Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHe HuangLZLulu Zhang

Discussion

Loading...

Member takes

Overview

Prospective trial shows promising efficacy of ZBR regimen in treatment-naïve follicular lymphoma, highlighting safety and response rates.

Key Points

  • Eighty percent complete response rate was observed in treatment-naïve advanced follicular lymphoma patients with ZBR regimen.
  • Objective response rate reached 100% among 32 evaluable patients, showing effectiveness beyond traditional therapies.
  • This phase II clinical trial aimed at safety and efficacy assessments in newly diagnosed follicular lymphoma patients.
  • ZBR regimen's safety profile was manageable, suggesting potential as a frontline treatment for advanced follicular lymphoma.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db31https://doi.org/10.1182/blood-2025-5363
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study2025
  2. 2Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  3. 3Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025
  4. 4Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis2025
  5. 5ZAP trial: MRD-guided chemotherapy and maintenance de-escalation with zanubrutinib-g-CHOP in high-risk FL (Phase II)2025